Table A-4.

Risk adjustment based on Treatment (Relative Risk Reduction)

Parameter	Base Case Value	Sensitivity Analysis Value	Source
Relative Risk in the Primary Prevention
Statin
CHD	0.75	0.71–0.78	Baigent 2005 (30)
Stroke	0.83	0.76–0.87	Baigent 2005 (30)
Aspirin
CHD	0.82	0.75–0.9	ATT Collaboration 2009 (56)
Stroke	0.95	0.85–1.06	ATT Collaboration 2009 (56)
Blood Pressure Treatment
CHD	0.84	0.79–0.9	Law 2009 (57)
Stroke	0.64	0.56–0.73	Law 2009 (57)
Relative Risk in the Secondary Prevention
Statin
Death	0.88	0.84–0.92	Cholesterol Treatment Trialists 2012 (31)
MI	0.76	0.73–0.79	Cholesterol Treatment Trialists 2012 (31)
Stroke	0.85	0.81–0.9	Cholesterol Treatment Trialists 2012 (31)
Aspirin
Death	0.91	0.82–1.00	ATT Collaboration 2009 (56)
MI	0.69	0.6–0.8	ATT Collaboration 2009 (56)
Stroke	0.81	0.71–0.92	ATT Collaboration 2009 (56)
ACE Inhibitor
Death	0.87	0.81–0.94	Baker 2009 (29)
MI	0.83	0.73–0.94	Baker 2009 (29)
Stroke	0.78	0.63–0.97	Baker 2009 (29)
Beta Blocker
Death	0.94	0.79–1.10	Lindholm 2005 (32)
MI	0.89	0.74–1.06	Lindholm 2005 (32)
Stroke	0.84	0.64–1.10	Lindholm 2005 (32)